A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease.

Emilie Mas, Anne Barden, Valerie Burke, Lawrence Beilin, Gerald Watts, Rae-Chi Huang, Ian Puddey, Ashley Irish, Trevor Mori

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)
959 Downloads (Pure)


Background and objective The high incidence of cardiovascular disease (CVD) in chronic kidney disease (CKD) is related partially to chronic inflammation. n-3 Fatty acids have been shown to have anti-inflammatory effects and to reduce the risk of CVD. Specialized Proresolving Lipid Mediators (SPMs) derived from the n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) actively promote the resolution of inflammation. This study evaluates the effects of n-3 fatty acid supplementation on plasma SPMs in patients with CKD. Methods In a double-blind, placebo-controlled intervention of factorial design, 85 patients were randomized to either n-3 fatty acids (4 g), Coenzyme Q10 (CoQ) (200 mg), both supplements, or control (4 g olive oil), daily for 8 weeks. The SPMs 18-HEPE, 17-HDHA, RvD1, 17R-RvD1, and RvD2, were measured in plasma by liquid chromatography–tandem mass spectrometry before and after intervention. Results Seventy four patients completed the 8 weeks intervention. n-3 Fatty acids but not CoQ significantly increased (P < 0.0001) plasma levels of 18-HEPE and 17-HDHA, the upstream precursors to the E- and D-series resolvins, respectively. RvD1 was significantly increased (P = 0.036) after n-3 fatty acids, but no change was seen in other SPMs. In regression analysis the increase in 18-HEPE and 17-HDHA after n-3 fatty acids was significantly predicted by the change in platelet EPA and DHA, respectively. Conclusion SPMs are increased after 8 weeks n-3 fatty acid supplementation in patients with CKD. This may have important implications for limiting ongoing low grade inflammation in CKD.
Original languageEnglish
Pages (from-to)331-336
Number of pages6
JournalClinical Nutrition
Issue number2
Publication statusPublished - 1 Apr 2016


Dive into the research topics of 'A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease.'. Together they form a unique fingerprint.

Cite this